| |
Bradykinin (1-5)  |
|
|
| Cat. No. |
Size |
Price |
Figures |
|---|
RP11131-5 mg
| 5 mg | $ 23.75 | HPLC: 20060721145620 (PDF)
MS: 20060721145600 (PDF)
MSDS: 20080709215947 (PDF)
STRUCTURE:
Zoom
References:
- Nieman MT, et al. Mapping the interaction of bradykinin 1-5 with the exodomain of human protease activated receptor 4. FEBS Lett. Jan 2005; 579(1): 25-29.
- Wu TJ, et al. Stimulation of luteinizing hormone-releasing hormone (LHRH) gene expression in GT1-7 cells by its metabolite, LHRH-(1-5). Endocrinology. Jan 2005; 146(1): 280-286.
- Dielis AW, et al. The prothrombotic paradox of hypertension: role of the renin-angiotensin and kallikrein-kinin systems. Hypertension. Dec 2005; 46(6): 1236-1242.
|
|---|
RP11131-25 mg
| 25 mg | $ 95.00 |
|---|
| Full Name | |
Sequence
(one-letter code) |
RPPGF | Sequence
(three-letter code) | {ARG}{PRO}{PRO}{GLY}{PHE} |
|---|
| Description | The bradykinin (BK) fragment (1-5) (RPPGF) is among the most stable of naturally occurring metabolites. Bradykinin (1-5) may be used as a marker for BK production in vivo. It is known that an intact Arg residue in the C-terminus is required for certain biological activities. BK 1-5 is the smallest peptide that can inhibit α-thrombin-induced platelet aggregation and secretion and calcium mobilization. Bradykinin (1-5) also prevents α-thrombin from cleaving the thrombin receptor peptide, NATLDPRSFLLR, between arginine and serine. Such antithrombin activities of BK 1-5 may contribute to the cardioprotective nature of kinins. |
|---|
| Formula | C27H40N8O6 |
|---|
| M.W. | 572.66 |
|---|
| Cas | 23815-89-6 |
|---|
| Purity | > 95% |
|---|
| Storage | Store the peptide at -20°C |
|
